|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: G3BP2 |
Gene summary for G3BP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | G3BP2 | Gene ID | 9908 |
| Gene name | G3BP stress granule assembly factor 2 | |
| Gene Alias | G3BP2 | |
| Cytomap | 4q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | A0A024RDE5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9908 | G3BP2 | LZE4T | Human | Esophagus | ESCC | 4.80e-06 | 1.41e-01 | 0.0811 |
| 9908 | G3BP2 | LZE7T | Human | Esophagus | ESCC | 1.84e-04 | 8.96e-01 | 0.0667 |
| 9908 | G3BP2 | LZE20T | Human | Esophagus | ESCC | 9.90e-05 | -1.50e-02 | 0.0662 |
| 9908 | G3BP2 | LZE21D1 | Human | Esophagus | HGIN | 4.49e-03 | -7.48e-02 | 0.0632 |
| 9908 | G3BP2 | LZE22D1 | Human | Esophagus | HGIN | 1.46e-07 | -9.60e-02 | 0.0595 |
| 9908 | G3BP2 | LZE22T | Human | Esophagus | ESCC | 1.30e-05 | 8.54e-02 | 0.068 |
| 9908 | G3BP2 | LZE24T | Human | Esophagus | ESCC | 5.97e-07 | 3.03e-01 | 0.0596 |
| 9908 | G3BP2 | LZE6T | Human | Esophagus | ESCC | 7.45e-05 | 5.01e-01 | 0.0845 |
| 9908 | G3BP2 | P1T-E | Human | Esophagus | ESCC | 2.28e-03 | 2.65e-01 | 0.0875 |
| 9908 | G3BP2 | P2T-E | Human | Esophagus | ESCC | 1.84e-42 | 9.44e-01 | 0.1177 |
| 9908 | G3BP2 | P4T-E | Human | Esophagus | ESCC | 3.27e-18 | 7.00e-01 | 0.1323 |
| 9908 | G3BP2 | P5T-E | Human | Esophagus | ESCC | 2.60e-11 | -2.34e-02 | 0.1327 |
| 9908 | G3BP2 | P8T-E | Human | Esophagus | ESCC | 1.48e-12 | 1.65e-01 | 0.0889 |
| 9908 | G3BP2 | P9T-E | Human | Esophagus | ESCC | 8.17e-22 | 8.24e-03 | 0.1131 |
| 9908 | G3BP2 | P10T-E | Human | Esophagus | ESCC | 8.43e-25 | 2.76e-01 | 0.116 |
| 9908 | G3BP2 | P11T-E | Human | Esophagus | ESCC | 1.23e-05 | 5.86e-01 | 0.1426 |
| 9908 | G3BP2 | P12T-E | Human | Esophagus | ESCC | 4.56e-19 | 3.12e-01 | 0.1122 |
| 9908 | G3BP2 | P15T-E | Human | Esophagus | ESCC | 1.15e-20 | 5.63e-01 | 0.1149 |
| 9908 | G3BP2 | P16T-E | Human | Esophagus | ESCC | 1.44e-28 | 5.82e-01 | 0.1153 |
| 9908 | G3BP2 | P17T-E | Human | Esophagus | ESCC | 3.07e-12 | 3.65e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000640320 | Esophagus | HGIN | RNA localization | 66/2587 | 201/18723 | 4.06e-12 | 5.41e-10 | 66 |
| GO:005065716 | Esophagus | HGIN | nucleic acid transport | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
| GO:005065816 | Esophagus | HGIN | RNA transport | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
| GO:005123616 | Esophagus | HGIN | establishment of RNA localization | 49/2587 | 166/18723 | 1.07e-07 | 5.47e-06 | 49 |
| GO:00510288 | Esophagus | HGIN | mRNA transport | 40/2587 | 130/18723 | 4.67e-07 | 2.07e-05 | 40 |
| GO:001593116 | Esophagus | HGIN | nucleobase-containing compound transport | 57/2587 | 222/18723 | 1.76e-06 | 6.52e-05 | 57 |
| GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
| GO:004518523 | Esophagus | HGIN | maintenance of protein location | 28/2587 | 94/18723 | 4.52e-05 | 1.09e-03 | 28 |
| GO:19021156 | Esophagus | HGIN | regulation of organelle assembly | 46/2587 | 186/18723 | 4.63e-05 | 1.12e-03 | 46 |
| GO:00340638 | Esophagus | HGIN | stress granule assembly | 10/2587 | 26/18723 | 1.60e-03 | 1.79e-02 | 10 |
| GO:00512205 | Esophagus | HGIN | cytoplasmic sequestering of protein | 9/2587 | 22/18723 | 1.64e-03 | 1.82e-02 | 9 |
| GO:0006403110 | Esophagus | ESCC | RNA localization | 166/8552 | 201/18723 | 1.95e-27 | 6.18e-25 | 166 |
| GO:005123617 | Esophagus | ESCC | establishment of RNA localization | 134/8552 | 166/18723 | 1.23e-20 | 1.81e-18 | 134 |
| GO:005102815 | Esophagus | ESCC | mRNA transport | 110/8552 | 130/18723 | 2.76e-20 | 3.80e-18 | 110 |
| GO:005065717 | Esophagus | ESCC | nucleic acid transport | 131/8552 | 163/18723 | 6.94e-20 | 8.46e-18 | 131 |
| GO:005065817 | Esophagus | ESCC | RNA transport | 131/8552 | 163/18723 | 6.94e-20 | 8.46e-18 | 131 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:0045185111 | Esophagus | ESCC | maintenance of protein location | 71/8552 | 94/18723 | 3.41e-09 | 7.24e-08 | 71 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| G3BP2 | SNV | Missense_Mutation | c.1264N>T | p.Asp422Tyr | p.D422Y | Q9UN86 | protein_coding | tolerated(0.1) | probably_damaging(0.994) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| G3BP2 | SNV | Missense_Mutation | c.884N>T | p.Arg295Leu | p.R295L | Q9UN86 | protein_coding | deleterious(0) | possibly_damaging(0.863) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| G3BP2 | SNV | Missense_Mutation | novel | c.1218G>C | p.Glu406Asp | p.E406D | Q9UN86 | protein_coding | deleterious(0.01) | possibly_damaging(0.515) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| G3BP2 | SNV | Missense_Mutation | c.1363N>A | p.Pro455Thr | p.P455T | Q9UN86 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.987) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| G3BP2 | SNV | Missense_Mutation | novel | c.346N>T | p.Pro116Ser | p.P116S | Q9UN86 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-OL-A5D6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| G3BP2 | SNV | Missense_Mutation | rs771668396 | c.116N>T | p.Ser39Phe | p.S39F | Q9UN86 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A5RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| G3BP2 | SNV | Missense_Mutation | rs267600258 | c.232C>T | p.Arg78Cys | p.R78C | Q9UN86 | protein_coding | tolerated(0.08) | benign(0.054) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| G3BP2 | SNV | Missense_Mutation | rs767685659 | c.1445N>A | p.Arg482His | p.R482H | Q9UN86 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.976) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| G3BP2 | SNV | Missense_Mutation | c.1178N>T | p.Pro393Leu | p.P393L | Q9UN86 | protein_coding | deleterious(0) | benign(0.216) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| G3BP2 | SNV | Missense_Mutation | novel | c.1160N>A | p.Arg387Lys | p.R387K | Q9UN86 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |